论文部分内容阅读
机体免疫应答的动态变化及空间差异是疾病精细化治疗的理论基础之一,同一免疫调节分子在不同时空条件下的功能可能截然不同。T细胞免疫球蛋白黏蛋白分子-3(T cell immunoglobulin and mucin-containing protein-3,TIM-3)是新近鉴定出的免疫检查点分子,与CTLA-4、PD-1等一样参与了免疫细胞稳态调控,TIM-3的异常高表达与肿瘤、慢性病毒感染的相关性使其成为免疫靶向治疗的关注点。靶向免疫检查点分子的临床治疗给患者带来了希望,但也存在效率不高、耐药乃至副作用明显等情况,问题的解决有赖于该类分子精细调控机制的阐明。大多数数据显示TIM-3具免疫抑制作用,但也有相反的报道。TIM-3的配体多样,胞内信号转导机制仍不十分明确。此外,血清中存在的可溶性TIM-3蛋白的功能及临床意义目前尚不清楚。如果免疫系统进化的过程中也赋予了TIM-3多重的免疫调节功能,阐明其调控机制必将对后续的应用研究提供重要参考。
The dynamic changes of body immune response and spatial differences are one of the theoretical foundations of disease fine treatment. The function of the same immunomodulatory molecule under different temporal and spatial conditions may be quite different. T cell immunoglobulin and mucin-containing protein-3 (TIM-3) are newly identified immune checkpoint molecules that are involved in immune cells like CTLA-4 and PD-1 Steady-state regulation, the abnormally high expression of TIM-3, and the association of tumor and chronic viral infections make it a focus of immune-targeted therapy. The clinical treatment of targeted immune checkpoint molecules brings hope to patients, but there are also some problems such as inefficiency, resistance and even obvious side effects. The solution to this problem depends on elucidation of the fine regulation mechanism of these molecules. Most data show TIM-3 has immunosuppressive effects, but also the opposite report. TIM-3 ligand diversity, intracellular signal transduction mechanism is still not very clear. In addition, the function and clinical significance of soluble TIM-3 protein present in serum is not clear. If immune system evolution also confers multiple immunomodulatory effects on TIM-3, its regulation mechanism will surely provide important reference for subsequent application research.